Crystal Structure of FMN-Dependent Nitroreductase from Escherichia coli B: A Prodrug-Activating Enzyme,
- 9 September 2000
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (20) , 3624-3631
- https://doi.org/10.1021/jm000159m
Abstract
The FMN-dependent flavoprotein nitroreductase from Escherichia coli B (NTR) is used in cancer chemotherapy to activate a range of prodrugs. The crystal structure of this enzyme has been determined, using molecular replacement methods and refined at 2.06 Å resolution. The recombinant 24-kDa enzyme was crystallized in the tetragonal space group P41212, with unit cell dimensions of a = b = 57.74 Å and c = 275.51 Å and two molecules in the asymmetric unit. The structure has a final R factor of 20.3% (Rfree = 26.7%), for all data between the resolution ranges of 10−2.06 Å, and includes 4453 protein atoms, 230 water molecules, and 2 flavin mononucleotide (FMN) molecules. The functional unit is a homodimer, which forms the asymmetric unit in the crystal structure. The tertiary structures of these two monomers and their subunit interactions are nearly identical. The molecular replacement search model, the crystal structure of the major NAD(P)H:FMN oxidoreductase of Vibrio fisheri (FRase 1), was selected on the basis of its high sequence identity to that of NTR. The final superposition of these two enzymes revealed a very similar overall fold, with variation in the structures focused around surface loops and helices near the FMN cofactor. Helix G is implicated in substrate specificity and is better resolved in the present NTR structure than in the previously reported FRase 1 structure. The FMN binding pocket is also well-resolved, showing the presence of two channels leading into the active site. The amino acid side chains and main chain atoms interacting with the FMN are well-ordered. The structure of the substrate binding pocket has been used to examine substrate specificity and enzyme kinetics for prodrugs used in antibody-directed enzyme prodrug therapy (ADEPT) and gene-directed enzyme prodrug therapy (GDEPT).Keywords
This publication has 13 references indexed in Scilit:
- Crystal Structure of Human DT-diaphorase: A Model for Interaction with the Cytotoxic Prodrug 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)Journal of Medicinal Chemistry, 1999
- 1.8 Å crystal structure of the major NAD(P)H:FMN oxidoreductase of a bioluminescent bacterium, Vibrio fischeri: overall structure, cofactor and substrate-analog binding, and comparison with related flavoproteinsJournal of Molecular Biology, 1998
- Mustard Prodrugs for Activation by Escherichia coli Nitroreductase in Gene-Directed Enzyme Prodrug TherapyJournal of Medicinal Chemistry, 1997
- Gene Cloning, Purification, and Characterization of NfsB, a Minor Oxygen-Insensitive Nitroreductase from Escherichia coli, Similar in Biochemical Properties to FRase I, the Major Flavin Reductase in Vibrio fischeriThe Journal of Biochemistry, 1996
- Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductaseBiochemical Pharmacology, 1995
- Crystallization and Preliminary Crystallographic Data for an FMN-dependent Nitroreductase from Escherichia coli BJournal of Molecular Biology, 1994
- PROCHECK: a program to check the stereochemical quality of protein structuresJournal of Applied Crystallography, 1993
- The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)—IBiochemical Pharmacology, 1992
- The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide)Biochemical Pharmacology, 1991
- Basic local alignment search toolJournal of Molecular Biology, 1990